US5364858A
(en)
*
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5053512A
(en)
*
|
1987-04-14 |
1991-10-01 |
Research Triangle Institute |
Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
|
US5122526A
(en)
*
|
1987-03-31 |
1992-06-16 |
Research Triangle Institute |
Camptothecin and analogs thereof and pharmaceutical compositions and method using them
|
US5106742A
(en)
*
|
1987-03-31 |
1992-04-21 |
Wall Monroe E |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5227380A
(en)
*
|
1987-03-31 |
1993-07-13 |
Research Triangle Institute |
Pharmaceutical compositions and methods employing camptothecins
|
US5049668A
(en)
*
|
1989-09-15 |
1991-09-17 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin analogs
|
US5180722A
(en)
*
|
1987-04-14 |
1993-01-19 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
|
US5340817A
(en)
*
|
1987-04-14 |
1994-08-23 |
Research Triangle Institute |
Method of treating tumors with anti-tumor effective camptothecin compounds
|
US5122606A
(en)
*
|
1987-04-14 |
1992-06-16 |
Research Triangle Institute |
10,11-methylenedioxy camptothecins
|
US4939255A
(en)
*
|
1987-06-24 |
1990-07-03 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic camptothecin derivatives
|
US5552154A
(en)
*
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
JP2684104B2
(ja)
*
|
1990-02-09 |
1997-12-03 |
株式会社ヤクルト本社 |
新規なカンプトテシン誘導体
|
EP0547165B1
(de)
*
|
1990-09-28 |
1999-11-10 |
Smithkline Beecham Corporation |
Verfahren zur Herstellung wasserlöslicher Camptothecinanaloge, sowie die Verbindungen 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
|
US5883255A
(en)
*
|
1990-10-31 |
1999-03-16 |
Smithkline Beecham Corporation |
Substituted indolizino 1,2-b!quinolinones
|
DE69233793D1
(de)
*
|
1991-02-21 |
2010-09-16 |
Glaxosmithkline Llc |
Pharmazeutische Zusammensetzung zur Verwendung in der Behandlung von Eierstockkrebs
|
WO1992014470A1
(en)
*
|
1991-02-21 |
1992-09-03 |
Smithkline Beecham Corporation |
Treatment of esophageal cancer
|
KR930702984A
(ko)
*
|
1991-02-21 |
1993-11-29 |
스튜어트 알. 슈터 |
비-소세포 폐암의 치료
|
US5559235A
(en)
*
|
1991-10-29 |
1996-09-24 |
Glaxo Wellcome Inc. |
Water soluble camptothecin derivatives
|
EP0540099B1
(de)
*
|
1991-10-29 |
1996-04-17 |
Glaxo Wellcome Inc. |
Wasserlösliche Camptothecinderivate
|
PT101061B
(pt)
*
|
1991-11-15 |
1999-07-30 |
Smithkline Beckman Corp |
Composicoes farmaceuticas contendo anagolos da camptotecina e um composto de coordenacao de platina e seu uso na inibicao do crescimento de celulas tumorais
|
EP0661977A1
(de)
*
|
1991-12-10 |
1995-07-12 |
Smithkline Beecham Corporation |
Behandlung von kolorektaler krebs
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
US5446047A
(en)
*
|
1992-07-23 |
1995-08-29 |
Sloan-Kettering Institute For Cancer Research |
Camptothecin analogues
|
US5391745A
(en)
*
|
1992-07-23 |
1995-02-21 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparation of camptothecin analogs
|
EP0655919A4
(de)
*
|
1992-08-21 |
1995-10-18 |
Dana Farber Cancer Inst Inc |
Behandlung von virusinfektionen beim menschen.
|
US5614549A
(en)
*
|
1992-08-21 |
1997-03-25 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5342947A
(en)
*
|
1992-10-09 |
1994-08-30 |
Glaxo Inc. |
Preparation of water soluble camptothecin derivatives
|
AP9300587A0
(en)
*
|
1992-11-12 |
1995-05-05 |
Glaxo Inc |
Water soluble camptothecin derivatives.
|
US5674872A
(en)
*
|
1993-08-20 |
1997-10-07 |
Smithkline Beecham Corporation |
Treatment of ovarian cancer
|
AU8052194A
(en)
*
|
1993-10-20 |
1995-05-08 |
Enzon, Inc. |
2'- and/or 7- substituted taxoids
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5436243A
(en)
*
|
1993-11-17 |
1995-07-25 |
Research Triangle Institute Duke University |
Aminoanthraquinone derivatives to combat multidrug resistance
|
US5447936A
(en)
*
|
1993-12-22 |
1995-09-05 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
|
GB9402934D0
(en)
*
|
1994-02-16 |
1994-04-06 |
Erba Carlo Spa |
Camptothecin derivatives and process for their preparation
|
US5468754A
(en)
*
|
1994-04-19 |
1995-11-21 |
Bionumerik Pharmaceuticals, Inc. |
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
|
US5604233A
(en)
*
|
1994-04-28 |
1997-02-18 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
|
WO1995029677A1
(en)
*
|
1994-04-28 |
1995-11-09 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin or 7-ethyl camptothecin
|
US5597829A
(en)
*
|
1994-05-09 |
1997-01-28 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin and methods for uses thereof
|
US5491237A
(en)
|
1994-05-03 |
1996-02-13 |
Glaxo Wellcome Inc. |
Intermediates in pharmaceutical camptothecin preparation
|
US5834442A
(en)
*
|
1994-07-07 |
1998-11-10 |
Barbara Ann Karmanos Cancer Institute |
Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
|
US5646159A
(en)
*
|
1994-07-20 |
1997-07-08 |
Research Triangle Institute |
Water-soluble esters of camptothecin compounds
|
US6504029B1
(en)
*
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
GB9510716D0
(en)
*
|
1995-05-26 |
1995-07-19 |
Pharmacia Spa |
Substituted camptothecin derivatives and process for their preparation
|
US5663177A
(en)
*
|
1995-05-31 |
1997-09-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
US5670500A
(en)
*
|
1995-05-31 |
1997-09-23 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
EP0835303A4
(de)
*
|
1995-06-07 |
2000-09-13 |
Univ Jefferson |
Anti-pilz agenzien und methoden zu deren identifizierung und verwendung
|
WO1997019085A1
(en)
*
|
1995-11-22 |
1997-05-29 |
Research Triangle Institute |
Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
|
US6395541B1
(en)
|
1996-05-23 |
2002-05-28 |
The Rockefeller University |
Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
|
DK0925301T3
(da)
*
|
1996-08-19 |
2004-07-12 |
Bionumerik Pharmaceuticals Inc |
Höjlipofile camptothecinderivater
|
US6013505A
(en)
|
1996-10-08 |
2000-01-11 |
Smithkline Beecham Corporation |
Topoisomerase I
|
US5962303A
(en)
*
|
1996-10-15 |
1999-10-05 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6025156A
(en)
*
|
1996-10-15 |
2000-02-15 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6559309B2
(en)
|
1996-11-01 |
2003-05-06 |
Osi Pharmaceuticals, Inc. |
Preparation of a camptothecin derivative by intramolecular cyclisation
|
EP1017675B1
(de)
*
|
1997-02-14 |
2006-06-14 |
Bionumerik Pharmaceuticals, Inc. |
Hochgradig lipophile camptothecin-derivate
|
US6207673B1
(en)
|
1997-03-12 |
2001-03-27 |
The University Of North Carolina At Chapel Hill |
Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
|
ID23424A
(id)
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
US6046209A
(en)
*
|
1997-05-27 |
2000-04-04 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
KR100289860B1
(ko)
*
|
1997-07-17 |
2001-05-15 |
나카무라 하사오 |
크로만의 제조 방법
|
US6011042A
(en)
*
|
1997-10-10 |
2000-01-04 |
Enzon, Inc. |
Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
|
US6214821B1
(en)
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
PT1102594E
(pt)
*
|
1998-08-05 |
2002-10-31 |
Aventis Pharma Sa |
Utilizacao de cloreto de sodio para reduzir a toxicidade gastrointestinal de derivados de camptotecina
|
EP2266607A3
(de)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
FR2801309B1
(fr)
*
|
1999-11-18 |
2002-01-04 |
Adir |
Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6288072B1
(en)
*
|
1999-12-29 |
2001-09-11 |
Monroe E. Wall |
Camptothecin β-alanine esters with topoisomerase I inhibition
|
YU64602A
(sh)
|
2000-02-28 |
2005-06-10 |
Aventis Pharma S.A. |
Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
|
US6548488B2
(en)
|
2000-03-17 |
2003-04-15 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
|
US6545010B2
(en)
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
AR027687A1
(es)
*
|
2000-03-22 |
2003-04-09 |
Yakult Honsha Kk |
Procedimiento para preparar camptotecina
|
US6486320B2
(en)
|
2000-09-15 |
2002-11-26 |
Aventis Pharma S.A. |
Preparation of camptothecin and of its derivatives
|
EP1333820A2
(de)
|
2000-10-27 |
2003-08-13 |
Aventis Pharma S.A. |
Zusammensetzungen zur behandlung von krebs, die camptothecin und stilbenverderivate enthalten
|
EP1335974A2
(de)
*
|
2000-11-14 |
2003-08-20 |
Emerald Biostructures Inc. |
Kristallzusammensetzungen der topoisomerase i
|
EP2316468A1
(de)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
|
US7462601B2
(en)
*
|
2002-03-26 |
2008-12-09 |
Tsutomu Kagiya |
Ameliorant for chemical treatment of cancer
|
ITRM20020306A1
(it)
*
|
2002-05-31 |
2003-12-01 |
Sigma Tau Ind Farmaceuti |
Esteri in posizione 20 di camptotecine.
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
WO2004055020A1
(en)
*
|
2002-12-16 |
2004-07-01 |
Council Of Scientific And Industrial Research |
Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
JP4477510B2
(ja)
*
|
2003-03-31 |
2010-06-09 |
カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ |
10−ヒドロキシ−4−(s)カンプトテンシンからトポテカンを調製する方法
|
CN100406460C
(zh)
*
|
2003-11-10 |
2008-07-30 |
中国科学院上海药物研究所 |
喜树碱的新衍生物、制备方法和用途
|
AR046579A1
(es)
*
|
2003-11-12 |
2005-12-14 |
Smithkline Beecham Corp |
Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
|
WO2005087808A2
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Growth factor binding constructs materials and methods
|
NZ550430A
(en)
*
|
2004-04-27 |
2009-06-26 |
Wellstat Biologics Corp |
Cancer treatment using viruses and camptothecins
|
US20050267141A1
(en)
|
2004-05-28 |
2005-12-01 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives
|
US20050272757A1
(en)
*
|
2004-06-04 |
2005-12-08 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
|
US7122700B2
(en)
*
|
2004-07-30 |
2006-10-17 |
Xerox Corporation |
Arylamine processes
|
US20090104254A1
(en)
|
2004-12-22 |
2009-04-23 |
Rutgers, The State University Of New Jersey |
Controlled Release Hydrogels
|
WO2012050591A1
(en)
|
2010-10-15 |
2012-04-19 |
Rutgers, The State University Of New Jersey |
Hydrogel formulation for dermal and ocular delivery
|
BRPI0606480A
(pt)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
JP5106098B2
(ja)
*
|
2005-02-28 |
2012-12-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の抗癌剤との新規併用
|
MX2007015407A
(es)
*
|
2005-07-14 |
2008-02-19 |
Wellstat Biologics Corp |
Tratamiento del cancer utilizando virus, fluoropirimidinas y camptotecinas.
|
EP1943253A1
(de)
*
|
2005-10-10 |
2008-07-16 |
Cipla Limited |
Neue kristalline formen
|
WO2007075492A1
(en)
*
|
2005-12-16 |
2007-07-05 |
Sonus Pharmaceuticals, Inc. |
Lipophilic anticancer drug compounds
|
US7547785B2
(en)
|
2005-12-26 |
2009-06-16 |
Dr. Reddy's Laboratories Limited |
Process for preparing topotecan
|
WO2007085370A1
(en)
*
|
2006-01-25 |
2007-08-02 |
Heidelberg Pharma Ag |
9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
|
CN101033230B
(zh)
*
|
2006-03-10 |
2010-12-08 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及其应用
|
WO2007113687A2
(en)
|
2006-03-30 |
2007-10-11 |
Diatos S.A. |
Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
|
WO2007127839A2
(en)
*
|
2006-04-26 |
2007-11-08 |
The Regents Of The University Of California |
Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
|
WO2008021549A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Sidney Kimmel Cancer Center |
Methods and compositions for topoisomerase i modulated tumor suppression
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
US7977483B2
(en)
*
|
2007-04-11 |
2011-07-12 |
Scinopharm Taiwan, Ltd. |
Process for making topotecan
|
US20080255175A1
(en)
*
|
2007-04-16 |
2008-10-16 |
Lam Marina K |
Anti-cancer agents, compositions and methods of treating cancers
|
KR20100016419A
(ko)
*
|
2007-04-19 |
2010-02-12 |
시노팜 타이완 리미티드 |
토포테칸 염산염의 결정형 및 그의 제조 방법
|
US8026249B2
(en)
*
|
2007-09-14 |
2011-09-27 |
Deutena Pharmaceuticals, Inc. |
Deuterium-enriched topotecan
|
ITMI20072268A1
(it)
|
2007-12-04 |
2009-06-05 |
Antibioticos Spa |
Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
|
WO2009145282A1
(ja)
*
|
2008-05-29 |
2009-12-03 |
メルシャン株式会社 |
カンプトテシン誘導体の製造方法
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
JP5793084B2
(ja)
|
2008-12-23 |
2015-10-14 |
ギリアド ファーマセット エルエルシー |
プリンヌクレオシドの合成
|
MX2011006890A
(es)
*
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
TW201026715A
(en)
|
2008-12-23 |
2010-07-16 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
DK2547359T3
(en)
|
2010-03-15 |
2016-06-06 |
The Board Of Trustees Of The Univ Of Illionis |
Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
|
PT2552930E
(pt)
|
2010-03-31 |
2015-11-17 |
Gilead Pharmasset Llc |
2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin- 1-(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2- il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropilo cristalino
|
RU2447076C1
(ru)
*
|
2010-12-09 |
2012-04-10 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Способ получения топотекана
|
WO2012082337A2
(en)
|
2010-12-17 |
2012-06-21 |
Glaxo Wellcome Manufacturing Pte Ltd |
Combination
|
WO2012083197A1
(en)
|
2010-12-17 |
2012-06-21 |
Nektar Therapeutics |
Water-soluble polymer conjugates of topotecan
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
EP2672969A4
(de)
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
Kombination
|
CA2850296C
(en)
|
2011-10-03 |
2021-01-12 |
Moreinx Ab |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
|
PL235836B1
(pl)
*
|
2012-10-25 |
2020-11-02 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
|
CN103113381B
(zh)
*
|
2013-02-26 |
2014-12-10 |
大连理工大学 |
系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
|
AR095962A1
(es)
|
2013-04-01 |
2015-11-25 |
Moreinx Ab |
Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
|
US10308719B2
(en)
|
2015-01-26 |
2019-06-04 |
The University Of Chicago |
IL13Rα2 binding agents and use thereof in cancer treatment
|
JP6912386B2
(ja)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なIL13Rα2を認識するCAR T細胞
|
JP6877049B2
(ja)
|
2015-09-25 |
2021-05-26 |
ゼットワイ セラピューティクス インク.Zy Therapeutics Inc. |
多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤
|
WO2017157825A1
(en)
|
2016-03-15 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
AU2017266724B2
(en)
*
|
2016-05-17 |
2022-04-14 |
Scandion Oncology A/S |
Combination treatment of cancer
|
MA49849A
(fr)
|
2017-08-07 |
2020-06-17 |
Amgen Inc |
Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
|
EP3669890A1
(de)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentöse nanopartikel mit impfstoffadjuvanswirkung
|
EP3941946A4
(de)
|
2019-03-20 |
2022-11-30 |
The Regents of the University of California |
Claudin-6-antikörper und wirkstoffkonjugate
|
JP2022525478A
(ja)
|
2019-03-20 |
2022-05-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
クローディン6二重特異性抗体
|
US20220160872A1
(en)
|
2019-04-09 |
2022-05-26 |
The Board Of Trustees Of The University Of Illinois |
Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
|
JP2022530241A
(ja)
|
2019-04-30 |
2022-06-28 |
インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス |
Cdk阻害剤と組み合わせたrank経路阻害剤
|
MX2021015937A
(es)
|
2019-06-24 |
2022-02-03 |
Amgen Inc |
Inhibicion de sirp-gamma para el tratamiento del cancer.
|
US20220265659A1
(en)
|
2019-09-02 |
2022-08-25 |
Inserm (Institut National De La Santé Et De Al Recherche Médicale) |
Methods and compositions for treating pax6-deficiency related disease
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
CN116478174A
(zh)
*
|
2022-07-29 |
2023-07-25 |
杭州爱科瑞思生物医药有限公司 |
喜树碱衍生物及其制备方法和应用
|